Silencing HMGB1 expression inhibits adriamycin's heart toxicity via TLR4 dependent manner through MAPK signal transduction

Date
2020
Author
Ekmekci, Sema Sirma
AKÇAKAYA, Handan
EMRENCE, Zeliha
ABACI, Neslihan
Sevgiler, Yusuf
Taskin, Eylem
Guven, Celal
Kaya, Salih Tunc
Sariman, Melda
Metadata
Show full item record
Abstract
Purpose: Adriamycin (APR) is a commonly used anti-cancer drug. ADR has toxic effects on cardiomyocytes and leads to heart failure. However, the underlying mechanism(s) by which ADR causes heart failure is still not clarified exactly. The aim of present study is to investigate whether ADR-induced heart failure is mediated via HMGB1/TLR4 to initiate the apoptosis through MAPK/AMPK pathways.
URI
http://hdl.handle.net/20.500.12627/96199
Collections